22/12/2025 – AB Science today announced that the United States Patent Office has formally granted a patent for methods of treating sickle cell disease using its lead compound masitinib, based on preclinical data Download PDF Post navigationPreviousPrevious post:AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per shareNextNext post:AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemiaRelated PostsAB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share18 December 2025AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers15 December 2025AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function11 December 2025AB Science announces the successful completion of a 2.8 million euros private placement17 October 2025Summary of the virtual conference held on October 16, 202516 October 2025AB Science webcast of October 16, 202516 October 2025
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share18 December 2025
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers15 December 2025
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function11 December 2025
AB Science announces the successful completion of a 2.8 million euros private placement17 October 2025